# EDGAR Filing Document

**Accession Number:** 0001253689
**File Stem:** 0000902664-25-002765
**Filing Date:** 2025-6
**Character Count:** 11635
**Document Hash:** 5f8a4cf5768ed00cb5e63e66a00aa3ac
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000902664-25-002765.hdr.sgml**: 20250620

**ACCESSION NUMBER**: 0000902664-25-002765

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250620

**DATE AS OF CHANGE**: 20250620

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GLYCOMIMETICS INC
- **CENTRAL INDEX KEY:** 0001253689
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-87811
- **FILM NUMBER:** 251061305

**BUSINESS ADDRESS:**
- **STREET 1:** 9708 MEDICAL CENTER DRIVE
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850
- **BUSINESS PHONE:** 240-243-1201

**MAIL ADDRESS:**
- **STREET 1:** 9708 MEDICAL CENTER DRIVE
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Adage Capital Management, L.P.
- **CENTRAL INDEX KEY:** 0001535978

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 200 CLARENDON STREET, 52ND FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
- **BUSINESS PHONE:** 617-867-2800

**MAIL ADDRESS:**
- **STREET 1:** 200 CLARENDON STREET, 52ND FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**GLYCOMIMETICS INC**

*(Name of Issuer)*

**Ordinary Shares, par value $0.001 per share**

*(Title of Class of Securities)*

**38000Q201**

*(CUSIP Number)*

**Robert Atchinson**<br>Adage Capital Partners GP, L.L.C.<br>200 Clarendon Street, 52nd Floor<br>Boston MA 02116<br>617-867-2800

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**06/20/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **38000Q201** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Adage Capital Management, L.P.** | Name of reporting person<br>**Adage Capital Management, L.P.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**50912.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**50912.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**50912.00** | Aggregate amount beneficially owned by each reporting person<br>**50912.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.37%** | Percent of class represented by amount in Row (11)<br>**0.37%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IA** | Type of Reporting Person (See Instructions)<br>**IA** | |

---

| **CUSIP No.** | **38000Q201** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Robert Atchinson** | Name of reporting person<br>**Robert Atchinson** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**50912.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**50912.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**50912.00** | Aggregate amount beneficially owned by each reporting person<br>**50912.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.37%** | Percent of class represented by amount in Row (11)<br>**0.37%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

| **CUSIP No.** | **38000Q201** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Phillip Gross** | Name of reporting person<br>**Phillip Gross** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**50912.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**50912.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**50912.00** | Aggregate amount beneficially owned by each reporting person<br>**50912.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.37%** | Percent of class represented by amount in Row (11)<br>**0.37%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Ordinary Shares, par value $0.001 per share

**(b) Name of Issuer:**
GLYCOMIMETICS INC

**(c) Address of Issuer's Principal Executive Offices:**
9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850

Comments (Optional): This Amendment No. 1 ("Amendment No. 1") amends and supplements the statement on Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on November 4, 2024 (the "Schedule 13D"), with respect to the ordinary shares, $0.001 par value per share (the "Ordinary Shares"), of Crescent Biopharma, Inc. (formerly known as GlycoMimetics, Inc.), a Cayman Islands exempted company (the "Issuer"). This Amendment No. 1 amends and restates Item 5 as set forth below and is being filed solely due to changes in the outstanding Ordinary Shares of the Issuer pursuant to the closing of the merger, and related transactions, on June 13, 2025 as contemplated by the Merger Agreement (the "Merger"), as described in the Current Report on Form 8-K filed by the Issuer with the SEC on June 18, 2025, as a result of which the Reporting Persons no longer beneficially own more than 5% of the Ordinary Shares. This Amendment No. 1 is the final amendment to the Schedule 13D, which the Reporting Persons are filing voluntarily to exit the reporting system.  Capitalized terms used herein and not otherwise defined in this Amendment No. 1 have the meanings set forth in the Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of Ordinary Shares and percentages of the Ordinary Shares beneficially owned by each of the Reporting Persons.  The percentages used in this Schedule 13D are calculated based upon 13,892,562 Ordinary Shares outstanding as of June 13, 2025 after giving effect to a 1-for-100 reverse stock split that was effected on June 13, 2025, the Merger and a redomestication that was effected on June 16, 2025, as disclosed in the Issuer's Current Report on Form 8-K, filed with the SEC on June 18, 2025.

**(b)**
See rows (7) through (10) of the cover pages to this Schedule 13D for the number of Ordinary Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.

The number of Ordinary Shares in this Schedule 13D give effect to the reverse stock split of 1-for-100 effected on June 13, 2025.

**(c)**
The Reporting Persons did not enter into any transactions in the Ordinary Shares during the past sixty days.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Adage Capital Management, L.P.

**Signature:** /s/ Robert Atchinson

**Name/Title:** By: Adage Capital Partners LLC, its General Partner, By: Robert Atchinson, its Managing Member

**Date:** 06/20/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Robert Atchinson

**Signature:** /s/ Robert Atchinson

**Name/Title:** Robert Atchinson, Individually

**Date:** 06/20/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Phillip Gross

**Signature:** /s/ Phillip Gross

**Name/Title:** Phillip Gross, Individually

**Date:** 06/20/2025